CD8A and neoplasm: Archaeosomes possess extremely high stability due to their unique chemical constitutions and have been shown to have a high safety profile and to activate antigen-specific CD8+ T cell responses in multiple studies to date, making them an appropriate choice for adjuvanting an anti-tumor vaccine [12].